Industry

DUBLIN–(BUSINESS WIRE)–The “Personal Care Contract Manufacturing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering. The global personal care contract manufacturing market reached a value of US$ 18.2 Billion in 2021. Looking forward, the publisher expects the market to reach a value of US$ 29.76 Billion … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Amoxicillin (CAS 61336-70-7) Global Market Research Report 2022” report has been added to ResearchAndMarkets.com’s offering. This global report is a result of industry experts’ diligent work on researching the world market of amoxicillin. The report helps to build up a clear view of the market trends and development, identify major players in the … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Pharmaceutical Quality Management – Risk Management and Regulatory Compliance, They are Complementary, Not Incompatible” webinar has been added to ResearchAndMarkets.com’s offering. The use of quality risk management in pharmaceutical operations does not preclude the requirement for a company’s compliance to all applicable regulations. The key is knowing how this process can be best … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Bacterial Endotoxin Test to Include the Latest on Low Endotoxin Recovery (LER)” webinar has been added to ResearchAndMarkets.com’s offering. The objective of this interactive webinar is to explore the new Guidance for Industry on Pyrogen and Endotoxins Testing which addresses those issues that may be subject to misinterpretation, and are not covered in … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “21 CFR Part 11, FDA’s Guidance for Electronic Records and Electronic Signatures” webinar has been added to ResearchAndMarkets.com’s offering. This webinar is intended for those involved in planning, execution and support of computer system validation activities, working in the FDA-regulated industries, including pharmaceutical, medical device, biologics, tobacco and tobacco-related products (e-liquids, e-cigarettes, pouch … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Overview of the Financial Aspects of Clinical Research” webinar has been added to ResearchAndMarkets.com’s offering. Leveraging case studies and federal regulations, attendees will learn about the phases of a clinical research study, an overview of Medicare billing guidelines and developing study budgets. Individuals supporting the financial aspects of a clinical research study must … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Troubleshooting Dissolution Methods for Solid Oral Dosage Forms” webinar has been added to ResearchAndMarkets.com’s offering. By attending this webinar, you will learn how to approach dissolution OOS/OOT investigations in a systematic, rigorous manner. Pharmaceutical dissolution testing for solid oral dosage forms is a complex analytical procedure where the control of critical variables (environmental … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Validation Sampling Plans” webinar has been added to ResearchAndMarkets.com’s offering. This webinar will discuss methods for setting up sampling plans depending on the risk profile of the final product or production step. It will go into using the sampling plan to set statistically justified acceptance criteria for the validation. All companies in the … [Read more…]

BAAR, Switzerland–(BUSINESS WIRE)–Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced positive data from its EfficAPSI real-world study. Presented at the 2022 European Academy of Allergy and Clinical Immunology (EAACI) congress in Prague (Czech Republic), the real-world study confirmed significant benefit of sublingual liquid allergen immunotherapy treatment (AIT) on the onset … [Read more…]

–Phase 2 trial showed chemotherapy-free TUKYSA combination resulted in clinically meaningful and durable tumor responses– –Results presented in late-breaking oral session at the ESMO World Congress on Gastrointestinal Cancer– BOTHELL, Wash.–(BUSINESS WIRE)–Seagen Inc. (Nasdaq:SGEN) today announced full results from the pivotal phase 2 MOUNTAINEER trial, which showed TUKYSA® (tucatinib) in combination with trastuzumab was well-tolerated … [Read more…]